

In the Claims

1. (Withdrawn) A method of screening drug candidates comprising:
 - a) providing a cell that expresses an expression profile gene encoding BCO2 or fragment thereof;
 - b) adding a drug candidate to said cell; and
 - c) determining the effect of said drug candidate on the expression of said expression profile gene.
2. (Withdrawn) A method according to claim 1 wherein said determining comprises comparing the level of expression in the absence of said drug candidate to the level of expression in the presence of said drug candidate.
3. (Withdrawn) A method of screening for a bioactive agent capable of binding to BCO2 or a fragment thereof, said method comprising:
 - a) combining said BCO2 or a fragment thereof and a candidate bioactive agent; and
 - b) determining the binding of said candidate agent to said BCO2 or a fragment thereof.
4. (Withdrawn) A method for screening for a bioactive agent capable of modulating the activity of BCO2, said method comprising:
 - a) combining BCO2 and a candidate bioactive agent; and
 - b) determining the effect of said candidate agent on the bioactivity of BCO2.
5. (Withdrawn) A method of evaluating the effect of a candidate breast cancer drug comprising:
 - a) administering said drug to a patient.
 - b) removing a cell sample from said patient; and
 - c) determining the expression of a gene encoding BCO2 or fragment thereof.
6. (Withdrawn) A method according to claim 5 further comprising comparing said expression profile to an expression profile of a healthy individual.
7. (Canceled).
8. (Withdrawn) An antibody which specifically binds to BCO2 or a fragment thereof.
9. (Withdrawn) The antibody of Claim 8, wherein said antibody is a

monoclonal antibody.

10. (Withdrawn) The antibody of Claim 8, wherein said antibody is a humanized antibody.

11. (Withdrawn) The antibody of Claim 8, wherein said antibody is an antibody fragment.

12. (Withdrawn) The antibody of Claim 8, wherein said antibody modulates the bioactivity of BCO2.

13. (Withdrawn) The antibody of Claim 12, wherein said antibody is capable of inhibiting the bioactivity of neutralizing the effect of BCO2.

14. (Withdrawn) A method for screening for a bioactive agent capable of interfering with the binding of BCO2 or a fragment thereof and an antibody which binds to BCO2 or fragment thereof, said method comprising:

- a) combining BCO2 or fragment thereof, a candidate bioactive agent and an antibody which binds to BCO2 or fragment thereof, and
- b) determining the binding of BCO2 or fragment thereof and said antibody.

15. (Withdrawn) A method according to Claim 14, wherein said antibody is capable of inhibiting or neutralizing the bioactivity of BCO2.

16. (Withdrawn) A method for inhibiting the activity of BCO2, said method comprising binding an inhibitor to BCO2.

17. (Withdrawn) A method according to Claim 16 wherein said inhibitor is an antibody.

18. (Withdrawn) A method of neutralizing the effect of BCO2 or a fragment thereof, comprising contacting an agent specific for said BCO2 or fragment thereof with said BCO2 or fragment thereof in an amount sufficient to effect neutralization.

19. (Withdrawn) A method of treating breast cancer comprising administering to a patient an inhibitor of BCO2.

20. (Withdrawn) A method according to Claim 19 wherein said inhibitor is an antibody.

21. (Withdrawn) A method for localizing a therapeutic moiety to breast cancer tissue comprising exposing said tissue to an antibody to BCO2 or fragment thereof conjugated to said therapeutic moiety.

22. (Withdrawn) A method of Claim 21, wherein said therapeutic moiety is a cytotoxic agent.

23. (Withdrawn) The method of Claim 21, wherein said therapeutic moiety is a radioisotope.

24. (Withdrawn) A method of treating breast cancer comprising administering to an individual having said breast cancer an antibody to BCO2 or fragment thereof conjugated to a therapeutic moiety.

25. (Withdrawn) The method of Claim 24, wherein said therapeutic moiety is a cytotoxic agent.

26. (Withdrawn) The method of Claim 21, wherein said therapeutic moiety is a radioisotope.

27. (Withdrawn) A method for inhibiting breast cancer in a cell, wherein said method comprises administering to a cell a composition comprising antisense molecules to a nucleic acid of figure 1.

28. (Withdrawn) A biochip comprising one or more nucleic acid segments encoding BCO2 or a fragment thereof, wherein said biochip comprises fewer than 1000 nucleic acid probes.

29. (Withdrawn) A method of eliciting an immune response in an individual, said method comprising administering to said individual a composition comprising BCO2 or a fragment thereof.

30. (Withdrawn) A method of eliciting an immune response in an individual, said method comprising administering to said individual a composition comprising a nucleic acid encoding BCO2 or a fragment thereof.

31. (Withdrawn) A method for determining the prognosis of an individual with breast cancer comprising determining the level of BCO2 in a sample, wherein a high level of BCO2 indicates a poor prognosis.

32. (Currently amended) A method for ~~determining the presence or absence of detecting~~ a breast cancer cell in a patient, the method comprising:

(i) detecting a nucleic acid ~~comprising a~~ encoding an amino acid sequence at least 75 90% identical to SEQ ID NO:1 2 in a sample from the patient, and

(ii) comparing expression levels of the nucleic acid in the sample from the patient

to expression levels of the nucleic acid in a normal tissue sample,

~~thereby determining the presence or absence of the breast cancer cell~~ wherein an increase in expression of the nucleic acid in the sample from the patient indicates the presence of a breast cancer in the patient.

33. (Currently amended) The method of claim 32, wherein the sample from the patient comprises isolated nucleic acids.

34. (Previously presented) The method of claim 32, wherein the nucleic acids are mRNA.

35. (Currently amended) The method of claim 32, wherein the sample from the patient is breast tissue.

36. (Previously presented) The method of claim 32, wherein the nucleic acid is SEQ ID NO:1.

37. (Currently amended) The method of claim 32, wherein said detecting step further comprises is carried out by using a labeled nucleic acid probe.

38. (Currently amended) The method of claim 32, wherein said detecting step ~~further comprises~~ is carried out by utilizing a biochip comprising a sequence at least ~~75~~ 90% identical to SEQ ID NO:1.

39. (New) The method of claim 32, wherein said detecting step is carried out by utilizing a biochip comprising a sequence at least 95% identical to SEQ ID NO:1.